Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela) in Chinese CKD Patients With Hyperphosphataemia

Next Previous
X
Search
Trial Profile

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela) in Chinese CKD Patients With Hyperphosphataemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Vifor Fresenius Medical Care Renal Pharma

    • Most Recent Events

    • 30 Apr 2021 According to a Vifor Fresenius Medical Care Renal Pharma media release, the company intends to submit the Chinese New Drug Application to the National Medical Products Administration's CDE at the end of 2021.
    • 30 Apr 2021 Results presented in the Vifor Fresenius Medical Care Renal Pharma Media Release.
    • 30 Apr 2021 Primary endpoint (Serum phosphorus (mmol/l )) has been met, according to a Vifor Fresenius Medical Care Renal Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top